Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study

Figure 3

In the case of the IVA group, the mCNV‐associated subretinal fluid totally regresses following two monthly IVA injections; the type I component of mCNV is still present at the following visit.